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Edited by Laszlo Nagy and Peter TontonozAbstract The control of physiological processes requires the
regulation and coordination of many diﬀerent signals and is
determined in part by the activation and repression of expression
of speciﬁc target genes. RIP140 is a ligand dependent coregula-
tor of many nuclear receptors that inﬂuence such diverse
processes as muscle metabolism, adipocyte and hepatocyte func-
tion, and reproduction. Recent evidence has shown that the abil-
ity of RIP140 to regulate nuclear receptor function is determined
by the relative level of RIP140 expression in comparison with
other cofactors, by post-translational modiﬁcations and by inter-
actions with additional transcription factors. As a result it is
becoming apparent that RIP140, via its interplay with other
coregulators, plays a fundamental role in determining both the
normal and pathogenic physiological state.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Nuclear receptors form a large superfamily of transcription
factors, many of which have an important role in regulating
the expression of gene networks that control metabolic pro-
cesses [1–3]. A role for nuclear receptors in metabolism has
been determined in part through the identiﬁcation of dietary-
related lipids as receptor ligands [4] and through the develop-
ment of model systems by genetic modiﬁcation. These studies
have shown that nuclear receptors are involved in the regula-
tion of energy homeostasis [5–7], either through their direct ef-
fects in metabolic tissues or indirectly via systemic signalling
pathways involving peripheral tissues or the central nervous
system. The ability of the receptors to integrate and regulate
metabolic pathways is largely determined by cofactors that
are capable of remodelling the state of chromatin in the vicin-
ity of target genes and modulating the function of the basic
transcription machinery. These cofactors or coregulators form
a large, diverse and growing group that are emerging as impor-
tant factors through which multiple signals converge to regu-
late speciﬁc cellular processes [8,9]. This is particularly the
case in metabolic tissues where the expression of coregulators,
their binding to nuclear receptors and their activity is deter-*Corresponding author.
E-mail address: m.parker@imperial.ac.uk (M.G. Parker).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.11.017mined by a combination of intrinsic factors such as intracellu-
lar metabolites that act directly as ligands and extrinsic stimuli
acting on cell surface receptors to trigger downstream signal-
ling pathways. For example, alterations in physical activity,
stress, body temperature and nutritional status can result in
the activation of distinct kinase cascades that induce post-
translational modiﬁcations. It is primarily through the devel-
opment of null mouse models however that coregulators such
as PGC-1a [6,10], PGC-1b [7], the p160 coactivators SRC-1
(NcoA-1/p160), SRC-2(TIF2/GRIP1/NcoA-2) and SRC-
3(pCIP/RAC3/ACTR/pCIP/AIB1/TRAM1) [11–14] and RIP140
[15] have been identiﬁed as important controlling factors in
metabolism which act as a second level of regulation compared
to nuclear receptors.
Gene transcription is a highly regulated process which in-
volves the recruitment and activity of multiprotein complexes
and the coordination and integration of many diﬀerent signals.
The global identiﬁcation of target genes for speciﬁc nuclear
receptors and cofactors such as RIP140 is beginning to provide
important evidence that shows how diverse signalling path-
ways are coordinated with regard to the control of gene expres-
sion. In addition, a number of recent studies have identiﬁed
coregulators, in the form of both coactivators and corepres-
sors, as important intermediary factors essential for the normal
activity of nuclear receptors in physiological processes. This
review will focus primarily on new evidence for the developing
concept of a fundamental role for RIP140 in normal cellular
function as well as in the pathology of metabolic tissues.2. Identiﬁcation and tissue speciﬁc expression of RIP140
RIP140 was ﬁrst identiﬁed and characterised as a hormone
dependent estrogen receptor interacting protein that was also
induced by estrogen treatment of breast cancer cells [16,17].
These initial studies indicated that alterations in the relative le-
vel of expression of RIP140 could modulate the activity of the
estrogen receptor in heterologous cells to result in either acti-
vation or repression of transcription of transiently transfected
target genes. In particular, at high levels of expression, repres-
sion by RIP140 was hormone dependent and required the pres-
ence of an intact receptor ligand binding domain.
The RIP140 gene is widely expressed but localised to speciﬁc
cell types within diﬀerent tissues. This is particularly apparent
in the ovary where expression is highly temporally and hor-
monally regulated during folliculogenesis and during preg-
nancy [18,19]. In common with the high degree of primary
amino acid sequence conservation between species, theblished by Elsevier B.V. All rights reserved.
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conserved. In particular the entire open reading frame (1161
amino acids in mouse, 1158 amino acids in human) is con-
tained within a large exon of approximately 7.3 kb. The high-
est levels of RIP140 expression however are found in metabolic
tissues, notably adipose tissue, liver and muscle [15]. Analysis
of skeletal muscle indicates that RIP140 is expressed in a ﬁbre
type speciﬁc manner with low expression in muscles that are
rich in oxidative ‘slow-twitch’ ﬁbres such as the soleus or the
diaphragm and relatively high levels of expression in muscles
that are rich in glycolytic ‘fast-twitch’ ﬁbres such as gastrocne-
mius and extensor digitorum longus [20]. The mouse RIP140
gene is localised on chromosome 16 (human chromosome
21) [21] and is transcribed from multiple promoters with the
major initiation site approximately 100 kb from the single cod-
ing exon [22]. Depending on the cell type, expression may be
regulated by a variety of hormones including estrogens [23],
retinoic acid [24], progestins [25] and vitamin D [26]. In adipo-
genesis in diﬀerentiating 3T3-L1 cells, the gene is transcribed
predominantly from exon 1b, also termed the P2 promoter
[22]. Expression studies and chromatin immunoprecipitation
experiments indicate that the orphan receptor ERRa stimu-
lates transcription from this promoter by two mechanisms, di-
rectly by binding to an ERE/ERRE at 650/633 and
indirectly through Sp1 binding sites near to the site of tran-
scriptional activation. Studies in breast cancer cells have iden-
tiﬁed a number of proximal and distal ERE elements which, in
response to estrogen stimulation, result in autoregulatory con-
trol of RIP140 expression [27,28]. In general therefore the pro-
cesses and mechanisms that regulate the levels of RIP140 in
metabolic tissues seem to enable a controlled and stable pat-
tern of expression to be maintained in diﬀerentiated cells.
In view of the complexity of its expression pattern, post-
translational regulation and the variety of transcription factor
targets it is perhaps not surprising that RIP140 has pleotropic
physiological eﬀects. The identiﬁcation and characterisation of
the roles of RIP140 has become apparent from the develop-
ment of a RIP140 null mouse model which has provided
important insights into the role and function of RIP140 in a
number of physiological processes. The demonstration that
RIP140 null mice are viable indicates that expression is not
essential for development, in contrast with other well charac-
terised nuclear receptor corepressors such as NCoR [29]. In
RIP140 null mice however, a variety of diﬀerent phenotypic
changes occur in speciﬁc tissues that result in major physiolog-
ical consequences. Interestingly in some tissues, such as skele-
tal muscle and the ovary the eﬀects seems to be highly
dependent on the relative levels of RIP140 expression, as
shown by the intermediate phenotypes in heterozygous ani-
mals[18,20]; while in others, such as adipose, this is much less
apparent. Whether this dosage eﬀect relates directly or indi-
rectly from tissue speciﬁc diﬀerences in target gene expression
is currently unknown. Interestingly, no related transcripts to
RIP140 have been identiﬁed by genome sequencing, however
a second ligand dependent coregulator termed LCoR has been
described which has some similar functional properties, in par-
ticular its recruitment to and repression of many nuclear recep-
tors [30]. As yet the possibility of functional compensation
between RIP140 and LCoR is still unclear.
A number studies carried out in diﬀerent laboratories have
demonstrated that RIP140 can repress the activity of many,if not all nuclear receptors, including some orphan receptors,
and that in some cases repression can occur in the absence
of added ligand [31,32]. RIP140 has also been identiﬁed as
an activator of reporter gene expression when coexpressed with
the AhR [33] or with other transcription factors including for
example AP1 or Sp1, the latter in combination with ERR iso-
forms and dependent on the organisation of the target gene
promoter [34,35]. Recent studies have also identiﬁed a role
for RIP140 as an activator of speciﬁc networks of genes in
the liver [36].3. Functional properties and mechanism of action of RIP140
The recruitment of RIP140 to nuclear receptors is mediated
by LXXLL motifs (where L is leucine and X is any amino
acid), alternatively termed NR boxes. There are nine motifs
in RIP140 [37] and a 10th LYYML motif (where Y is tyrosine
and M is methionine) at the C-terminus of the protein which
seems to bind selectively to both retinoid receptors [38] and
to LXRb [39]. All 10 motifs are highly conserved between spe-
cies in both their primary sequence and position. The presence
of a relatively high number of NR-interaction motifs in
RIP140 in comparison to other LXXLL containing coregula-
tor proteins may allow some functional redundancy in the
interaction of RIP140 with diﬀerent classes of receptor. Studies
have shown that certain NRs have a clear preference for spe-
ciﬁc RIP140 NR boxes [40–42]. Similarly small fragments of
RIP140 can interact in either a ligand dependent or ligand
independent way with a particular NRs [43] and in addition
to sequence speciﬁcity of each motif, mechanisms such as the
level of expression of RIP140 or post-translational modiﬁca-
tions may also modulate these interactions.
RIP140 seems to function primarily as a scaﬀold protein that
links nuclear receptors to chromatin remodelling enzymes in-
volved in chromatin condensation and transcriptional repres-
sion. Four distinct repression domains (RDs) have been
identiﬁed in RIP140 [44] that may act as binding sites for
diﬀerent repressive enzymatic complexes. The mechanism of
repression for both RD1 and RD2 involves recruitment of
HDAC modifying enzymes [45] however RD3 and RD4 are
yet to be fully characterised.
The repressive function of RIP140 can be modulated by
post-translational modiﬁcations which include phosphoryla-
tion on up to 11 diﬀerent residues, the functional consequences
of which are increased HDAC3 recruitment leading to en-
hanced repression [46]. Conversely, the biological activity of
the corepressor is inhibited by arginine methylation [47]. Mod-
iﬁcations have also been identiﬁed on lysine residues, one of
which is the novel lysine 613 conjugation of pyridoxal 5 0-phos-
phate, the biologically active form of vitamin B6, that results
in enhanced repressive activity [48]. Nine lysines have been
identiﬁed in RIP140 that may be targets for acetylation one
of which, (lysine 446) when acetylated prevents recruitment
of an additional transcriptional repressor protein, C-terminal
binding protein (CtBP) [49]. This speciﬁc site is within the
RD2 repression domain. In total, four motifs that facilitate
CtBP recruitment have been identiﬁed in RIP140. Two of
these, PIDLS [44,49,50] and PINLS [44,50] are required for
repression by RD2. A summary of the functional domains
and sites of post translational modiﬁcation in RIP140 is shown
1 200 400 600 800 1000 1158
RD1 RD2 RD3 RD4
1 2 3 4 5 6 7 8 9 10
CtBP
LXXLL
CtBP VitB6
Fig. 1. Functional domains and sites of post translational modiﬁca-
tion of RIP140. The scale bar indicates the size of the human RIP140
protein in terms of amino acid sequence. LXXLL motifs and the
LXXML motif are shown in blue labelled (1–10). Positions of the 4
repression domains RD1–RD4 are marked. Stars indicate positions of
potential sites of lysine acetylation and the vertical bars show positions
of the interaction sites for CtBP and for covalent modiﬁcation by
vitamin B6. The protein contains approximately 15% serine/threonine
residues and sites identiﬁed as phosphorylation targets are omitted for
clarity.
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recruitment mediated by the binding of CtBP. This may be
partially relieved by the HDAC inhibitor TSA suggesting that
CtBP is acting via HDAC-dependent and independent mecha-
nisms.
CtBP is a dehydrogenase that has also been shown to func-
tion as a redox sensor in that changes in NADH/NAD+ ratio
may aﬀect its repressive function [51–53]. Large changes in cel-
lular redox state occur in certain metabolic abnormalities, such
as diabetes, and alterations in the intracellular redox status by
increasing the concentration of NAD(P)H are reported to re-
duce the amount of abdominal adipose tissue [54,55]. Thus,
the repressive activity of RIP140 may be subject to ﬂuctuations
in cellular redox potential mediated by CtBP.4. Identiﬁcation of target genes and a role for RIP140 in
metabolism
The comparison of gene expression proﬁles from normal tis-
sue and cells with RIP140 null tissues and cell lines has identi-
ﬁed many potential target genes that are regulated by RIP140
expression. Analysis of ovarian, adipose and muscle gene
expression proﬁles from wild-type and RIP140 null mice ob-
tained from Aﬀymetrix DNA microarrays has identiﬁed
changes in gene networks and possible rate-limiting factors
important for tissue speciﬁc and metabolic changes. Analysis
of the microarray data has shown that although RIP140 has
been shown to function primarily as a corepressor for nuclear
receptors the overall number of genes that were up-regulated
in the absence of RIP140 was very similar to the total number
of down-regulated genes in all cases [20,32]. In contrast, cluster
analysis of genes ascribed to speciﬁc metabolic pathways in
both adipose tissue and muscle demonstrated that 33% of
genes were upregulated and only 4% were downregulated, con-
sistent with the function of RIP140 as a corepressor. The vast
majority of upregulated genes in both adipose and muscle were
involved in catabolic pathways including fatty acid oxidation,
oxidative phosphorylation, glycolysis, and the tricarboxylic
acid cycle with many of the upregulated genes common to both
tissue types [20,32,56].
Interestingly in this metabolic pathway gene cluster analysis
the expression of only seven genes in WAT and ﬁve genes inmuscle were downregulated in the absence of RIP140 and in-
cludes genes which are involved in anabolic pathways, in par-
ticular fatty acid and triglyceride synthesis. The expression
proﬁling studies in adipocytes and muscle tissue also revealed
increased expression of genes involved in mitochondrial bio-
genesis and activity in the absence of RIP140. In particular
in adipose tissue and cultured adipocytes a number of genes
which are normally restricted to expression in brown adipo-
cytes are markedly derepressed in white adipose tissue. An
example of this is the gene coding for the mitochondrial
uncoupler UCP1. Consistent with all these changes in gene
expression adipocytes depleted of RIP140 show elevated oxy-
gen consumption, fatty acid b-oxidation and insulin stimulated
glucose uptake [32,56].
Skeletal muscle in both mouse and humans contains distinct
types of ﬁbres that are characterized by the expression of spe-
ciﬁc myosin heavy chain isoforms. Thus diﬀerent skeletal mus-
cles are adapted for diﬀerent types of contractile function
according to the ﬁbre types they contain. Type I ﬁbres, also
known as slow twitch ﬁbres, are rich in mitochondria and ex-
hibit high levels of oxidative phosphorylation making them
resistant to fatigue. Type II, or fast twitch ﬁbres, contain a re-
duced number of mitochondria and rely more on anaerobic
respiration via glycolysis or glycogenolysis to enable them to
undergo rapid, short contractile bursts. Thus in comparison
to type I ﬁbres, type II ﬁbres are more prone to fatigue [57].
There is also an intermediate type of muscle ﬁbre, termed type
IIX, that has fast twitch characteristics, but depends on a level
of oxidative metabolism that is similar to type I ﬁbres [58]. In
response to environmental factors such as for example an in-
crease in load or exercise ﬁbre types can switch, as shown by
the appearance of oxidative type I ﬁbres. This switch in ﬁbre
type is reﬂected in changes in the expression of myosin iso-
forms and other ﬁbre type markers and is accompanied by in-
creased expression of genes involved in mitochondrial
biogenesis, fatty acid oxidation and oxidative phosphoryla-
tion.
In RIP140 null mice the EDL and gastrocnemius, muscles
that normally express relatively high levels of RIP140, exhibit
a change to contain more oxidative ﬁbres appearing redder in
colour and expressing elevated levels of type I markers. These
changes are accompanied by increased mitochondrial number
which is coordinated with an up regulation of genes involved
in oxidative metabolism, most notably fatty acid oxidation
[20]. In contrast, muscles that consist of predominantly type
I ﬁbres that normally express low levels of RIP140 show a lar-
gely unaltered phenotype in the RIP140 null mice. The impor-
tance of the expression level of RIP140 as a major determining
factor in muscle physiology is demonstrated by the observation
that over expression of RIP140 in muscle results in a reduction
in oxidative ﬁbres and an increase in glycolytic markers [20].
This suggests that in common with adipose tissue, RIP140
functions to repress oxidative metabolism and mitochondrial
function in skeletal muscle.5. Nuclear receptor targets of RIP140 and cofactor interplay
An important characteristic of many metabolic genes is that
they are transcribed at a basal level yet can be readily activated
or repressed in relation to the nutritional or physiological
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lation of metabolic gene expression and mitochondrial func-
tion has identiﬁed it as a coregulator that shares a number
of features in common with the PGC-1 family of polypeptides.
In particular there is a remarkable similarity between RIP140
and PGC-1a and PGC-1b target genes, with RIP140 primarily
repressing and the PGC-1 cofactors activating, suggesting a
functional interplay between these coregulators which is an
integral part in the regulation of metabolic processes. In brown
adipocytes Ucp1 expression, which is a critical component of
the adaptive thermogenic response [59], is largely dependent
on PGC-1a activity with this coactivator acting as a focus
for signals from diﬀerent sources. In addition to extracellular
stimuli a number of nuclear receptors that are PGC-1a targets
are implicated in the regulation of expression of Ucp1 [60],
including PPARc and PPARa, TRs, RXRs and ERRa [61].
The derepression of Ucp1 expression in adipocytes in the ab-
sence of RIP140, the enhanced response to diﬀerent ligands,
together with the observation that RIP140 is localised on the
Ucp1 enhancer demonstrates that this gene is a common target
for both coregulators.
In skeletal muscle the expression of genes involved in mito-
chondrial function and oxidative phosphorylation is elevated
in type I ﬁbres compared with type II ﬁbres. Many of these
genes has been shown to be targets for the nuclear receptors
PPARd [62] and ERRa, with the latter acting in part by acti-
vating PPARa [63]. There is also a major role for PPARd, in
regulating ﬁbre type switching as shown by expression of a
constitutively transcriptionally active form of this receptor
resulting in an increase in type I ﬁbres and an associated in-
crease in endurance [62].
The PGC-1 coactivators have been shown to be important
factors in the transition of muscle ﬁbre type. PGC1a expres-
sion in skeletal muscle varies according to ﬁbre type with high-
er levels in slow twitch type I muscles such as the soleus
muscle, and lower levels in type II muscles such as extensor
digitorum longus [64]. Muscle speciﬁc expression of PGC-1a
in transgenic mice at a level at which this coactivator, in type
II ﬁbres, is similar to that normally found in type I ﬁbres, has
been shown to be suﬃcient to switch type II ﬁbres to type I and
increase expression of mitochondrial genes to result in resis-
tance to fatigue [64]. Exercise training is also known to induce
a switch to greater type I ﬁbres within skeletal muscle and this
could be explained by enhanced PGC-1a expression induced
by exercise that results in an induction of mitochondrial genes
such as cytochrome c [65]. In agreement with these observa-
tions, one line of PGC1a null mice show reduced mass of typ-
ical slow twitch type I muscles with a preservation of type II
ﬁbres [6]. This is accompanied by a reduction in mitochondrial
number and expression of mitochondrial genes in muscle and a
reduced capacity to sustain exercise. PGC-1b is also expressed
in muscle, and transgenic mice overexpressing PGC-1b exhibit
increased mitochondrial biogenesis and show induction of type
IIX oxidative fast twitch ﬁbres [66]. PGC-1b null mice have re-
duced mitochondrial mass in the soleus muscle [7] thus PGC1b
seems to promote the formation of oxidative type IIX ﬁbres.
The PGC-1 coactivators are involved in the control of expres-
sion of many key muscle metabolic genes which are targeted by
nuclear receptors, for example ERRa or PPARd, or by muscle
speciﬁc transcription factors such as MEF2D [9]. In muscle
cells RIP140 also targets the promoters of PPARd target genes
such as MCAD and the ERRa target gene FABP3 [20]. Thediscovery of alternative roles for RIP140 and PGC-1 in the
regulation of expression of speciﬁc genes together with the
identiﬁcation of similar nuclear receptors as potential targets
suggests an important functional interplay between these
coregulators.
In addition to adipose and muscle tissue, PGC-1a and b
have been demonstrated to be important regulators of liver
function; however a detailed analysis of the relative impor-
tance of each PGC-1 isoform in this tissue and the identiﬁca-
tion and analysis of the mechanisms of action are still an
open question. PGC-1a is not required for lipogenesis but is
an important regulator of gluconeogenesis and hepatic lipo-
protein metabolism and is also an important factor for many
aspects of the response to fasting. In contrast, PGC-1b has
no signiﬁcant eﬀect on gluconeogenesis but has been reported
to increase lipogenesis and lipoprotein transport while
PGC1bKO mice show lipid accumulation in the liver and a de-
crease in plasma triglyceride-rich VLDL lipoproteins when fed
a high fat diet [7]. A number of nuclear receptors and other
transcription factors have been described to be involved in
the recruitment of PGC-1 to target genes in liver cells [67]
including HNF4a, LXR, PPARa, SREBP1c, CREB, FOXO1
and FOXA2, although in many cases only a subset of genes for
any one factor is subject to induction by the coactivators. Re-
cent studies have now identiﬁed a hepatocyte speciﬁc role for
RIP140 as a cofactor for LXR in diﬀerent ways, namely serv-
ing as a coactivator in lipogenesis and as a corepressor in glu-
coneogenesis [36]. In common with the complex eﬀects of
PGC-1 in hepatocytes, RIP140 also acts on a subset of genes
in each of these processes, for example, both PEPCK and
G6Pase levels are decreased in normal mice when treated with
an LXR agonist (T0901317) but PEPCK repression is not
maintained in RIP140 null mice. Similarly the repression of
PEPCK gene expression by LXR is dependent on RIP140 in
hepatocytes in culture while expression of G6Pase is unaf-
fected. These studies, in line with those in cultured adipose
and muscle cells demonstrate an intrinsic eﬀect of RIP140 in
each speciﬁc cell type and therefore suggest that RIP140 has
an important role in cell physiology. A list of genes identiﬁed
as direct targets for RIP140 by chromatin immunoprecipita-
tion is shown in Table 1.6. Is RIP140 a metabolic counterbalance?
The evidence emerging from both in vivo studies and cellular
systems has identiﬁed a role for RIP140 as an important regu-
latory factor in many metabolic processes. In particular the
types of genes which are now shown to be RIP140 targets,
their regulation by speciﬁc nuclear receptors such as ERRa
and the PPARs known to be key factors in metabolic tissues
combined with the opposing eﬀects of RIP140 and the PGC-
1 cofactors suggests that RIP140 can function as a counterbal-
ance in the regulation of metabolism by coregulators. In addi-
tion to the control of expression of key enzymes or markers of
diﬀerentiated cells such as Ucp1 in adipose tissue and speciﬁc
myosin isoforms in muscle; one of the most fundamental re-
sults from the current studies is the identiﬁcation of a role
for RIP140 in mitochondrial function. Whether RIP140 pri-
marily aﬀects basal mitochondrial activity, adaptive mitochon-
drial responses, or both of these processes is still to be
Table 1
Genes identiﬁed as direct targets of RIP140
Tissue/cell type Gene Nuclear receptor/
transcription factor
Reference
Adipose/adipocytes ucp1 PPARs, ERRa [32]
Myocytes fabp3 PPARd [20]
mcad ERRa [20]
HuH7 hepatocytes FAS LXR [36]
FAO hepatocytes pepck LXR [36]
MCF-7 cells TMC4 ER/ AP1 [28]
IRX4 ER/AP1 [28]
GUSB ER/AP1 [28]
MUC1 ER/AP1 [28]
C10ORF18 ER/AP1 [28]
LNCaP PSA AR [73]
Hela MAO-B ER/ERR [74]
H295R human
adrenocortical cells
CYP17 SF1 [75]
Fig. 2. Model for a central role for RIP140 and in the function of
metabolic tissues. RIP140 acts as a counterbalance to control basal
and regulated metabolic activity, mainly through functional interplay
with PGC-1a and PGC-1b. Gene targets for RIP140 in metabolic
tissues are determined primarily by nuclear receptors and are depen-
dent on ligands in addition to other nuclear receptor cofactors. The
action of these coregulator pathways is also subject to the eﬀects of
other tissue speciﬁc signalling pathways and through interactions with
tissue speciﬁc transcription factors.
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RIP140 is further complicated due to the compensatory roles
of the diﬀerent PGC-1 coregulators combined with tissue spe-
ciﬁc factors and signals (Fig. 2). Whatever the precise details of
the mechanisms involved, it is clear that RIP140 is an impor-
tant factor in energy homeostasis.7. RIP140 and connections to disease
One of the major determining factors in the development of
metabolic disorders is abnormal energy expenditure. It is prob-
able therefore that a number of coregulatory factors such as
RIP140, PGC-1a and b and the p160 proteins SRC1-3, via
their ability to repress or activate anabolic and catabolic func-
tions, may act as important elements in the progression of dis-ease. It is perhaps surprising therefore that as yet there is
relatively little evidence for a role for RIP140 in health and dis-
ease. RIP140 null mice do not show evidence of lipodystrophy
and exhibit normal insulin sensitivity when fed a high fat diet.
They are also protected from the development of insulin resis-
tance induced by either aging or high fat feeding, however it is
as yet unclear to what extent the loss of RIP140 in muscle, adi-
pose, liver or other tissues plays in terms of whole animal phys-
iology. Nuclear receptors have now been shown to be
important targets for drugs to treat diabetes and associated as-
pects of the metabolic syndrome. The ﬁbrate class of drugs
used to treat dyslipidaemia have been found to be potent
PPARa ligands [68] and the thiozolinodione (TZD) class used
to treat type 2 diabetes (Rosiglitazone and Pioglitazone) func-
tion as PPARc agonists [69]. TZDs have been shown to im-
prove insulin sensitivity and lower blood glucose levels in
type 2 diabetes. In murine white adipocytes, the induction of
UCP-1 expression following treatment with rosiglitazone is
dramatically increased by the depletion of RIP140 [61] suggest-
ing that RIP140 may inhibit the eﬀects of PPARc ligands to
induce expression of genes associated with energy expenditure.
The PPARc ligand pioglitazone, when given to human subjects
with type 2 diabetes, increases mitochondrial number in adi-
pose tissue and the expression of many genes associated with
oxidative metabolism such as MCAD and CPT1 as well as
UCP-1, perhaps mediated via an increase in PGC1a expression
[70]. In support of these ﬁndings rosiglitazone treatment in-
creases UCP-1 expression in white adipocytes when PGC1a
is overexpressed [71]. Despite these changes in gene expression,
which might be predicted to increase energy expenditure both
pioglitazone and rosiglitazone increase body weight, in part
through an expansion of adipose tissue. Several combined
PPAR a and c ligands have also been developed to treat multi-
ple aspects of the metabolic syndrome and diabetes [72]
however the clinical outcomes of using these drugs have also
not always been as expected. It is conceivable that some of
the complex eﬀects of treatment with PPAR ligands may be
explained by the eﬀects these agents have on diﬀerential
recruitment of co-activators or co-repressors to the receptor
following ligand binding.
It is interesting to speculate that the lack of a clear association
of RIP140 with disease may be a consequence of the pleotropic
nature ofRIP140.Overexpression ofRIP140 or factors that lead
to an increase in activity of RIP140would be predicted to impair
mitochondrial function and in a coregulator-counterbalance
model this would be compensated for by an increase in the activ-
ity of other coregulators such as the PGC-1 family. Loss of func-
tion of RIP140 however, although not deleterious as shown by
the RIP140 null mouse model, would result in complete infertil-
ity and hence any genetic link to health or the incidence of
disease unlikely to occur. Clearly while coactivators such as
PGC-1a can be induced or regulated in response to metabolic
demand it is essential that basal metabolic function is also care-
fully controlled to maintain normal cell function.8. Conclusions and future studies
It is emerging that transcriptional coregulator proteins pro-
vide an important level of control in a number of metabolic
processes. RIP140, via its ligand dependent association with
44 R. White et al. / FEBS Letters 582 (2008) 39–45nuclear receptors, may therefore provide an important target
for intervention in the control and regulation of metabolic dys-
function. An integral part of this process will be the identiﬁca-
tion of natural and synthetic ligands that allow speciﬁc or
temporal recruitment of coactivators or corepressors such as
RIP140 to nuclear receptors. Further studies will be necessary
to determine the relative importance of RIP140 expression ver-
sus post-translational modiﬁcations in speciﬁc cell types such
as muscle, liver and adipocytes. In addition further analysis
of tissue speciﬁc signalling pathways will be required, as these
may account for the intermediate phenotypes shown in certain
types of tissue. It may also be relevant to recall that RIP140
was originally identiﬁed as a regulator of estrogen action in
breast cancer cell lines and therefore may play a role in meta-
bolic activity in tumour cells and therefore potentially in the
growth or progression of hormone dependent tumours. Finally
in view of the fundamental role of RIP140 in mitochondrial
activity it will be important to determine the role of RIP140
signalling in the function of other cell types such as macro-
phages and neural cells in which metabolic dysfunction has
been shown to be an important factor in the development of
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